Abstract 1649: Mechanistic understanding of HPK1 inhibition on enhanced human T cell activation and tumor immunity in a syngeneic model
David Ciccone(Harvard University), Neelu Kaila, Vad Lazari(Charles River Laboratories (United Kingdom)), Alan Collis, Joshua McElwee(Merck & Co., Inc., Rahway, NJ, USA (United States)), Peter J. Tummino(Intarcia Therapeutics (United States)), Samantha Carreiro(Ensemble Therapeutics (United States)), Christine Loh(Ensemble Therapeutics (United States)), Michael A. Briggs(Charles River Laboratories (United Kingdom)), Ian D. Linney(Charles River Laboratories (United Kingdom))
Cited by 1
Related Papers
Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori
|Nature|1999|1.9k
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
|Nature|2012|1.8k
Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase
|Journal of Biological Chemistry|2002|1.4k
Immune dysregulation in human subjects with heterozygous germline mutations in <i>CTLA4</i>
|Science|2014|844
Residence Time of Receptor−Ligand Complexes and Its Effect on Biological Function
|Biochemistry|2008|550